<DOC>
	<DOCNO>NCT01112059</DOCNO>
	<brief_summary>The purpose study examine role well-known well-tolerated antibiotic , doxycycline , treatment cystic fibrosis patient hospitalize . This antibiotic effectively treat bacteria airway cystic fibrosis patient , may reduce activity inflammatory molecule disease .</brief_summary>
	<brief_title>Trial Doxycycline Reduce Sputum MMP-9 Activity Adult Cystic Fibrosis ( CF ) Patients</brief_title>
	<detailed_description>One molecule inhibit doxycycline matrix metalloprotease-9 , emerge important mediator lung inflammation damage cystic fibrosis . We hypothesize addition treatment doxycycline CF inpatient reduce MMP-9 activity inflammatory marker sputum cystic fibrosis patient compare CF patient treat doxycycline .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>Cystic Fibrosis Hospitalization Pulmonary exacerbation Significant GI illness Participation another Investigational Protocol Allergies Doxycycline Sputum Culture positive Staphylococcus aureus , Pregnant Nursing Unwilling use effective birth control Elevated LFT 's great 3x upper limit normal Creatinine great 1.5x upper limit normal Lung transplantation Substance abuse within 30 day screen</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>cystic fibrosis</keyword>
</DOC>